RSS

HEMP Hemp, Inc.

Mod: StanleyK
Last Post: 09/30/23
Followers: 82
Posts Today: 0
Views Today: 4519

HEMP Stock Quote & Tools

$0.0000 ▲ +0.0000 (+0.00%) As of Nov 10, 3:22 PM EST
Last0.0000
$ Chg0.0000
Open0.0000
High0.0000
Beta7.9076
Year High0.000
Market Cap23.7K
P/B Ratio—
EPS0.00
Avg Vol (30d)1.85M
Volume1.48M
% Chg+0.00%
Prev Close0.0000
Low0.0000
VWAP0.00000
Year Low0.000
Total Shares23.74B
Shares Out23.74B
Float23.74B
ExchangeOTCID
Healthcare Pharmaceuticals

HEMP Stock Message Board Discussion

  1. mountaineer

Top 10 Most Recent News Articles

Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 188

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 373

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 351

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 607

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 144

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 103

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 133

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 136

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 79

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 232

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring AI's Impact on CRM Visibility and Brand Trust

Updated Category News Views 217

Understanding the Role of AI in CRM Visibility Brandi AI has recently launched its AI Visibility Index series, which offers insightful measurements of how industries are perceived in AI-generated responses. This new series highlights the ways in which customer relationship management (CRM) brands are represented through the lens of advanced AI answer engines. The AI...

Continue Reading
Celldex Therapeutics Thrives Amid Developments with Briquilimab

Updated Category News Views 148

Overview of Celldex Therapeutics and Briquilimab Celldex Therapeutics (NASDAQ: CLDX) is navigating an exciting phase as it explores treatments for chronic conditions like Chronic Inducible Urticaria (CIndU). Analysts have closely observed the efficacy of briquilimab, highlighting its performance through recent studies. Analyst Insights on Celldex and Briquilimab Goldman...

Continue Reading
XPENG's Financial Success in Q3 2024: Key Insights Revealed

Updated Category News Views 238

XPENG's Journey in the Third Quarter of 2024 XPeng Inc. (“XPENG” or “the Company,” NYSE: XPEV and HKEX: 9868) recently disclosed its financial results for the third quarter ended September 30, 2024. This marks a significant period showcasing growth in revenues and vehicle deliveries, reflecting the company's robust strategy in the smart electric vehicle market....

Continue Reading
Apple Inc. Beats Earnings Expectations: Analysts React

Updated Category News Views 144

Apple Inc. Overcomes Challenges with Strong Quarterly Results Apple Inc.‘s latest quarterly performance has generated significant buzz in the tech world. Analysts reveal that the results showcase a resilient company navigating through various market challenges. This performance not only reflects strong sales of products like the iPhone but also highlights impressive...

Continue Reading
Class Action Alert: Investors Have Rights with AMMO, Inc.

Updated Category News Views 237

Class Action Lawsuit Against AMMO, Inc. In a proactive move for investors, Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against AMMO, Inc. (NASDAQ: POWW). This suit comes in light of significant losses experienced by investors in the company due to alleged misstatements and omissions regarding its business practices. Understanding the Class...

Continue Reading